Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Impaired Fasting Glucose Clear all

Conditions: Impaired Fasting Glucose
Interventions: psyllium, Microcrystalline Cellulose; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pre-diabetes
Interventions: Sitagliptin, Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 35 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome, Impaired Glucose Tolerance, Disorder of Glucose Regulation
Interventions: Metformin XR plus placebo, Metformin XR plus liraglutide; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Impaired Glucose Tolerance
Interventions: Sildenafil, Placebo, Hyperglycemic clamp, Euglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Obesity
Interventions: Sitagliptin Phosphate; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy, Obesity & Overweight, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes)
Interventions: Not listed
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 59 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Prediabetes
Interventions: metformin, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions: Dapagliflozin, Saxagliptin, Pioglitazone, Metformin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions: Placebo, Colesevelam; Drug
Lead sponsor: Radiant Research; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more

Conditions: Pre-diabetes, Type 2 Diabetes
Interventions: Exenatide, Sitagliptin, Glimepiride; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Hyperglycemia, Diabetes Mellitus
Interventions: Lantus® (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Prediabetes, Hyperglycemia, Postprandial Hyperglycemia, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions: Sweetch App + DBWS, Sweetch App Alone; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Reading, Pennsylvania

Conditions: Diabetes Mellitus, Impaired Fasting Glucose, Prediabetes
Interventions: Re-infusion of biotin labeled cells, Diabetes education/diabetes medication adjustment; Biological · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
Interventions: Dexamethasone 2.5 mg and Sitagliptin 100 mg, Dexamethasone 2.5 mg and placebo tablet; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: South Burlington, Vermont

Conditions: Disorder of Glucose Regulation
Interventions: Sitagliptin-Metformin, Metformin, Placebo pill; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Impaired Fasting Glucose, Pre Diabetes, Liver Fat
Interventions: Dietary intervention; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Impaired Glucose Tolerance, Oxidative Stress, Prediabetes, Impaired Fasting Glucose
Interventions: low glycemic index (LGI) diet, high glycemic index (HGI) diet plus placebo (PLAC), high glycemic index diet plus N-acetylcysteine; Other · Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Interventions: insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 12,537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Impaired Glucose Tolerance, Obesity, Diabetes
Interventions: Physical Activity Counseling; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 60 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 88
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more

Conditions: Isolated Impaired Fasting Glucose
Interventions: Low-calorie diet, Routine dietary and physical activity habits; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Bone Metabolism
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: Up to 70 Years · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 34
States / cities: Greenbrae, California • Los Banos, California • San Diego, California + 31 more

Conditions: Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
Interventions: REMD-477, Placebo Subcutaneous injection; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Obesity, Pre-diabetes, Insulin Resistance, Impaired Glucose Tolerance, Impaired Fasting Glucose
Interventions: Chromium; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Derby, Connecticut

Search by objective public record fields.

Comparison of Psyllium and Microcrystalline Cellulose on Glycemic Measures in Subjects With Impaired Fasting Glucose

Incretins in Impaired Fasting Glucose

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Renin-Angiotensin and Fibrinolysis in Humans: Effect of Long-Term PDE5 Inhibition on Glucose Homeostasis

Incretin Effect in People With Impaired Fasting Glucose

Growth Hormone Resistance of Beta-cells

Metformin and Muscle in Insulin-resistant Older Veterans

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

Lantus in Prediabetes

Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes

Effect of Red Blood Cell Survival on a Commonly Used Diabetes Lab Test-HbA1c

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

Dietary Interventions in Prediabetes

Effect of Dietary Glycemic Index on Beta-cell Function

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Enhancing Fitness in Older Pre-diabetic Veterans

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Low-calorie Diet in Isolated Impaired Fasting Glucose

Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Chromium Effects on Insulin and Vascular Function in People at Risk for Diabetes